Literature DB >> 3032874

Importance of HLA-DQ and -DP restriction elements in T-cell responses to soluble antigens: mutational analysis.

E Mellins, M Woelfel, D Pious.   

Abstract

We describe a new approach to delineating the restriction elements used by antigen-specific human T-cell lines. EBV-transformed B cell lines and congenic HLA class II antigen-loss mutants are used to present soluble antigen to immune T cells. In this way it is possible to assess the independent contribution of individual class II loci to the restriction repertoire of the T cells. In contrast to results obtained with other methods of restriction element analysis, we find that approximately 40% of the T-cell response to several antigens is restricted by non-DR class II molecules. Both mutational analysis and blocking by class II specific monoclonal antibodies demonstrate that the non-DR restricted responses derive from DQ and DP-encoded determinants. We also find specific DR/DQ haplotype preferences for the presentation of some but not all antigens. Using a mutant that expresses only the DQ1 molecule, and is derived from a DR1, DQ1 parent line, we demonstrate a functional split of serologically defined DQ1 molecules consistent with the electrophoretic variation reported between DQ1 molecules linked to DR1 and those linked to DR2. Pairs of mutants that differ by expression of a single class II protein reveal a much broader use of available class II restriction elements than previously recognized.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3032874     DOI: 10.1016/0198-8859(87)90086-3

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  12 in total

1.  Point mutations define positions in HLA-DR3 molecules that affect antigen presentation.

Authors:  E Mellins; B Arp; D Singh; B Carreno; L Smith; A H Johnson; D Pious
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

Review 2.  Antigen presenting cells.

Authors:  D L Hamilos
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

3.  Mechanisms by which HLA-class II molecules protect human B lymphoid tumour cells against NK- and LAK-mediated cytolysis.

Authors:  P I Lobo; M Y Chang; E Mellins
Journal:  Immunology       Date:  1996-08       Impact factor: 7.397

4.  Role of HLA-DP in the Presentation of Epitopes from the Truncated Bacterial PE38 Immunotoxin.

Authors:  Ronit Mazor; Selamawit Addissie; Youjin Jang; Chin-Hsien Tai; Jeremy Rose; Fran Hakim; Ira Pastan
Journal:  AAPS J       Date:  2016-10-27       Impact factor: 4.009

5.  Importance of HLA-DQ and HLA-DP polymorphisms in cytokine responses to naturally processed HLA-DR-derived measles virus peptides.

Authors:  Inna G Ovsyannikova; Robert A Vierkant; Gregory A Poland
Journal:  Vaccine       Date:  2006-05-03       Impact factor: 3.641

6.  Replacement of the DR alpha chain with the E alpha chain enhances presentation of Mycoplasma arthritidis superantigen by the human class II DR molecule.

Authors:  T Sawada; R Pergolizzi; K Ito; J Silver; C Atkin; B C Cole; M D Chang
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

7.  Association between HLA DQB1 * 03 and cervical intra-epithelial neoplasia.

Authors:  K Odunsi; G Terry; L Ho; J Bell; J Cuzick; T S Ganesan
Journal:  Mol Med       Date:  1995-01       Impact factor: 6.354

8.  T-lymphocyte clones responsive to Shigella flexneri.

Authors:  S H Zwillich; A D Duby; P E Lipsky
Journal:  J Clin Microbiol       Date:  1989-03       Impact factor: 5.948

9.  A single amino acid substitution in the human histocompatibility leukocyte antigen DR3 beta chain selectively alters antigen presentation.

Authors:  E Mellins; B Arp; B Ochs; H Erlich; D Pious
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

10.  A gene required for class II-restricted antigen presentation maps to the major histocompatibility complex.

Authors:  E Mellins; S Kempin; L Smith; T Monji; D Pious
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.